IN VIVO: Deals Shaping The Medical Industry, May 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
You may also be interested in...
Promotion does not adequately communicate the diabetes drug’s indication, limits of use and risks, FDA says. It objects to distracting visuals in video and less prominent risk information. Agency had previously relayed its concerns to Lilly about Trulicity promotions.
Around 1,500 senior and junior management roles will be cut under Unilever’s announced plan to reshape its corporate matrix, the firm reports on 25 January. The news comes a day after reports that activist investor Nelson Peltz of Trian Fund Management has taken a stake in the business.
The Public Access to Sunscreens Coalition suggests the FDA should stay in its regulatory lane or at least await the results of a National Academies of Sciences study before moving forward with an environmental impact statement to the US Environmental Protection Agency regarding certain UV filters under GRASE review reported to harm marine coral.